Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trazodone + gabapentin
- Development stage
- Phase 2
- Lead developer
- Angelini Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Trazodone + gabapentin is a combination of two pharmaceutical drugs, each with distinct mechanisms of action, investigated for synergistic effects in the management of neuropathic pain and potentially other conditions. Trazodone is an antidepressant classified as a serotonin receptor antagonist and reuptake inhibitor (SARI), primarily blocking post-synaptic serotonin 5-HT2A and 5-HT2C receptors while inhibiting presynaptic serotonin reuptake. Gabapentin is a GABA analogue that exerts its effect mainly by binding to the α2δ subunit of voltage-gated calcium channels, reducing presynaptic glutamate release. Preclinical studies and early clinical trials suggest that low-dose combinations may provide enhanced antinociceptive (pain-relieving) effects compared to either drug alone, likely due to their complementary mechanisms[2][4][6]. This combination has been studied particularly in the context of neuropathic pain such as painful diabetic neuropathy.
- Other names
- trazodone hydrochloride
02
Targets
HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)DRD2 (Dopamine D2 Receptor)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on trazodone + gabapentin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trazodone + gabapentin.